Asset profile
DA-1241
Small molecule
Evidence outlook · lead readout
NCT03061981 · Diabetes Mellitus, Type 2
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03061981: Participants were randomized and both they and study staff were fully blinded, with a placebo comparator, but the primary endpoint was safety and tolerability rather than a disease outcome, and no results are yet posted, so what the trial ultimately shows is still unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.